Safiya Saad Dhaif

Safiya Saad Dhaif

Auto-generated profile, based on publicly available information

Safiya Saad Dhaif

National Diabetes Center, Mustansiriyah University, Iraq

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2023 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
GJGhufran S. Jaber
Ghufran S. Jaber
SDSafiya Saad Dhaif
Safiya Saad Dhaif
THThuraya A. Abdul Hussian
Thuraya A. Abdul Hussian
NINatier A. Ibrahim
Natier A. Ibrahim
AAAchmad Arifiyanto
Achmad Arifiyanto

20 September 2025 in SHIFAA
Verified
Journal Article
Open access
PDF file
SDSafiya Saad Dhaif
Safiya Saad Dhaif
HAHanan Al-Naymi
Hanan Al-Naymi
AHAshjan Mohammed Hussain
Ashjan Mohammed Hussain
TATareq Hafdi Abdtawfeeq
Tareq Hafdi Abdtawfeeq
AZAyat Majeed Zeadan
Ayat Majeed Zeadan
NINathier A. Ibrahim
Nathier A. Ibrahim
Diabetes, a chronic metabolic disorder and silent killer, results from insufficient insulin production or utilization, leading to systemic complications. This study integrates global diabetes data with a local sample from the National Diabetes Center, Mustansiriyah University (Baghdad, Iraq) to provide a comparative perspective. Global data from the *International Diabetes Federation* and *IHME Global Burden of Disease* were analyzed and visualized. Additionally, 50 diabetic patients under treatment and follow-up at the National Center were statistically evaluated using paired sample t-tests in SPSS. Worldwide, diabetes cases reached 536.6 million and are projected to rise to 783.2 million by 2045 (+46%). Undiagnosed cases (239.7 million) and deaths (7.1 million, +71% since 2011) were concentrated in the Western Pacific. Locally, paired t-test results (t = 7.73, t = 8.49, p < 0.001) confirmed significant differences pre- and post-intervention, indicating strong treatment response. By integrating global trends with local patient data, this study highlights the dual challenge of rising prevalence and underdiagnosis worldwide, contrasted with evidence of effective treatment outcomes at a local specialized center.

1 June 2025 in Studia Biologica
Verified
Journal Article
Open access
PDF file
SDSafiya Saad Dhaif
Safiya Saad Dhaif
DMDhuha Badr Mahmood
Dhuha Badr Mahmood
GJGhufran Salman Jawad
Ghufran Salman Jawad
LGLujain Ali Ghannawi
Lujain Ali Ghannawi
HAHaidar Fadhil Al-Rubaye
Haidar Fadhil Al-Rubaye
Background. Staphylococcus aureus, is a major pathogen causing infections in both hospital and community settings. Multi-drug-resistant strains, particularly Methicillin-resistant Staphylococcus aureus (MRSA), complicate treatment, as these strains can evade antibiotics. Biofilm formation by S. aureus protects bacterial cells from immune responses and antibiotics, making infections difficult to treat. This study evalua­tes the synergistic effect of silver nanoparticles (AgNPs) and cefotaxime in inhibiting biofilm formation by clinical S. aureus isolates, especially multi-drug-resistant strains. Materials and Methods. Thirty clinical S. aureus isolates were obtained from patients with skin infections. Identification was confirmed using biochemical tests and the VITEK2 system. Antimicrobial susceptibility testing was performed using the disk diffusion method on antibiotics including ciprofloxacin, imipenem, amoxicillin-clavulanic acid, cefotaxime, and chloramphenicol. Minimum inhibitory concentrations (MICs) were also determined. Biofilm formation was quantified using crystal violet staining. Silver nanoparticles (AgNPs) were synthesized using sodium borohydride and characterized by atomic force microscopy (AFM) and field emission scanning electron microscopy (FE-SEM). Results. All isolates were susceptible to ciprofloxacin and imipenem. Ninety percent were susceptible to amoxicillin-clavulanic acid, while 70% were susceptible to cefotaxime. All isolates were resistant to chloramphenicol. Biofilm formation assays showed variability in biofilm production. AgNPs alone demonstrated superior efficacy in inhibiting biofilm formation. The combination of AgNPs and cefotaxime exhibited the strongest inhibition, suggesting a synergistic effect. Conclusion. This study suggests that AgNPs alone are more effective than cefotaxime in inhibiting biofilm formation. The combination of AgNPs and cefotaxime showed the most potent effect, providing a promising strategy for treating multi-drug-resistant S. aureus infections. AgNPs may serve as an adjunct to antibiotics in overcoming biofilm-associated infections.